Lymphocyte Stimulation Assays Did Not Directly Measure Clinical Immune Failure
A laboratory response of cultured lymphocytes is different from a patient’s demonstrated susceptibility to infection. A historical cannabis chapter discussed altered cell-stimulation responses, but those assays cannot simply be relabeled as a clinical diagnosis of immune failure.
The measurements were made after cell collection
Nahas described lymphocyte studies using stimulation by phytohemagglutinin and mixed-cell procedures. The assays examined cellular responses, including incorporation of a DNA-synthesis marker.
The chapter compared cannabis users with other groups, including people with established illnesses or immunosuppressive treatment. It also acknowledged an age difference between the cannabis group and a healthy comparison group.
Similar assay values do not establish equivalent illness
Two groups can have similar results on one laboratory measure while differing greatly in clinical condition, medication exposure and underlying causes. A comparable mean does not demonstrate an identical mechanism or prognosis.
A stimulation assay does not directly count infections, measure recovery from disease or establish the clinical consequences of a particular exposure. Those outcomes require their own observations.
Preserve the distinction when using historical evidence
The chapter argued for immunological concern, but its interpretation should remain distinguishable from the assay findings it summarized. Group selection, co-exposures and the relationship between a surrogate and patient outcomes all require attention.
This is an analysis of an older research claim. It does not establish that cannabis users have the same immune condition as transplant or cancer patients, nor does it provide a current individual risk estimate.
Related: Separating cannabis exposure and impairment.
Research cited
Gabriel G. Nahas. Marihuana: Toxicity and Tolerance. Historical book chapter, pp. 16–36.
